Mary Relling and her research group at St. Jude Children’s Research Hospital (SJCRH) is one of the world’s key players in the development and implementation of personalized medicine, and her research addresses personalized medication therapy in general addressing the more than 200 genome variants affecting approximately 100 drugs for which there are sufficient data to allow adaptation of individualized therapy.
Most recently, professor Relling has turned her attention to developing the infrastructure and methodology to implement array-based methods of broadly integrating pharmacogenetic variants into clinical care. In 2009, she formed the Clinical Pharmacogenetics Implementation Consortium (CPIC), a joint effort between PharmGKB and the US National Institute of Health Pharmacogenomics Research Network. This consortium now involves over 130 members from 14 countries, who write peer-reviewed, freely available, and updatable practical guidelines on how to adjust drug therapy based on genetic test results.
Professor Relling has more than 290 scientific papers, in total cited 1741 times in 2013, and she has an H-index of 76 with 19 publications within the last 15 years in Nature, Nature Genetics, Science, Lancet, or the New England Journal of Medicine.
Henrik Enghusen Poulsen
Klinisk Farmakologisk Afdeling